SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Andrew H who wrote (19405)4/22/1998 2:08:00 PM
From: Henry Niman  Respond to of 32384
 
Here's more good news for LGND:
Wednesday April 22 1:10 PM EDT

Estrogen Reduces Risk Of Parkinson's Dementia

NEW YORK (Reuters) -- Women with Parkinson's disease who also take estrogen replacement therapy may significantly
reduce their risk of developing the dementia often associated with the disease, according to experts at Columbia University in
New York.

Many patients with Parkinson's disease also develop a form of dementia that is clinically similar to Alzheimer's disease.
Unfortunately, the medications used to treat parkinsonian tremors often cause confusion in patients with dementia, so their
Parkinson's symptoms often remain untreated. But if doctors could find a way to prevent or delay the development of dementia
in patients with Parkinson's disease, they "...could have greater flexibility in treating motor disorders such as tremors, rigidity,
slowness and stiffness, and this may prolong a patient's life," Dr. Karen Marder, a neurologist at Columbia, says in a statement
from the journal Neurology.

Marder and colleagues studied the effect of estrogen use on the risk of Parkinson's disease-associated dementia in 87 women
with Parkinson's disease without dementia, 80 women with Parkinson's disease with dementia, and almost 1,000 nondemented
healthy women, all drawn from the same community.

They found that estrogen replacement therapy in this group "...did not affect the risk of Parkinson's disease but may have been
associated with a lower risk of dementia in women with Parkinson's disease." In fact, in Parkinson's patients who used estrogen
replacement therapy, the risk of dementia decreased by more than 75% compared with Parkinson's patients who did not take
estrogen replacement therapy.

Marder says in a related statement, "Women with Parkinson's disease who reported using estrogen reduced their risk of
dementia by almost five times." She speculates, "Larger doses of estrogen could give women greater protection against
developing dementia."

Since estrogen has been shown to have a protective effect against Alzheimer's disease, the findings indicate that, at least in a
subset of patients, Parkinson's disease dementia may in fact be coincident Alzheimer's disease. The authors point out in their
report in the April issue of Neurology that their findings are preliminary and should be confirmed in a larger clinical trial.
SOURCE: Neurology (1998;50:1141-1143)